{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:20:20Z","timestamp":1759666820892,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"DOI":"10.3389\/fsurg.2020.00026","type":"journal-article","created":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T04:26:15Z","timestamp":1591331175000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients"],"prefix":"10.3389","volume":"7","author":[{"given":"Idir","family":"Ouzaid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sol\u00e8ne Florence","family":"Kammerer-Jacquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zineddine","family":"Khene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Jacques","family":"Patard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Bensalah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Rioux-Leclercq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.eururo.2014.10.002","article-title":"International variations and trends in renal cell carcinoma incidence and mortality","volume":"67","author":"Znaor","year":"2015","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eururo.2016.11.034","article-title":"Updated European Association of urology guidelines regarding adjuvant therapy for renal cell carcinoma","volume":"71","author":"Bex","year":"2017","journal-title":"Eur Urol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/01.ju.0000165572.38887.da","article-title":"Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system","volume":"174","author":"Lam","year":"2005","journal-title":"J Urol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2146\/ajhp080387.p1","article-title":"Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 1","volume":"66","author":"Cersosimo","year":"2009","journal-title":"Am J Health Syst Pharm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2146\/ajhp080387.p2","article-title":"Renal cell carcinoma with an emphasis on drug therapy of advanced disease, part 2","volume":"66","author":"Cersosimo","year":"2009","journal-title":"Am J Health Syst Pharm."},{"key":"B6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clgc.2018.01.003","article-title":"Adjuvant therapies in nonmetastatic renal-cell carcinoma: a review of the literature","volume":"16","author":"Bandini","year":"2018","journal-title":"Clin Genitourin Cancer."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","article-title":"Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma","volume":"35","author":"Motzer","year":"2017","journal-title":"J Clin Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","article-title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"387","author":"Haas","year":"2016","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1200\/JCO.2004.09.104","article-title":"Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study","volume":"22","author":"Patard","year":"2004","journal-title":"J Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1053\/hupa.2001.28957","article-title":"Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma","volume":"32","author":"Rioux-Leclercq","year":"2001","journal-title":"Hum Pathol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.euf.2015.06.001","article-title":"Wild-type VHL clear cell renal cell carcinomas are a distinct clinical and histologic entity: a 10-year follow-up","volume":"1","author":"Dagher","year":"2016","journal-title":"Eur Urol Focus."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/j.clgc.2018.12.011","article-title":"Adjuvant tyrosine kinase inhibitors in treatment of renal cell carcinoma: a meta-analysis of available clinical trials","volume":"17","author":"Massari","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cell.2018.03.057","article-title":"Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell."},{"key":"B15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.cell.2018.03.043","article-title":"Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell."},{"key":"B16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nature09639","article-title":"Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma","volume":"469","author":"Varela","year":"2011","journal-title":"Nature."},{"key":"B18","doi-asserted-by":"publisher","first-page":"E157","DOI":"10.1111\/bju.12426","article-title":"Polybromo-1 (PBRM1), a SWI\/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma","volume":"113","author":"da Costa","year":"2014","journal-title":"BJU Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"E11","DOI":"10.1002\/ijc.27822","article-title":"Loss of PBRM1 expression is associated with renal cell carcinoma progression","volume":"132","author":"Paw\u0142owski","year":"2013","journal-title":"Int J Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1002\/cncr.24238","article-title":"Complexity of tumor vasculature in clear cell renal cell carcinoma","volume":"115","author":"Qian","year":"2009","journal-title":"Cancer."},{"key":"B21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1158\/1078-0432.CCR-06-0774","article-title":"Two distinct types of blood vessels in clear cell renal cell carcinoma have contrasting prognostic implications","volume":"13","author":"Yao","year":"2007","journal-title":"Clin Cancer Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1109\/TBME.2018.2860932","article-title":"Ultrasound measurement of vascular density to evaluate response to anti-angiogenic therapy in renal cell carcinoma","volume":"66","author":"Rojas","year":"2019","journal-title":"IEEE Trans Biomed Eng."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1158\/1078-0432.CCR-18-1724","article-title":"Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory pharmacogenomic analysis","volume":"25","author":"George","year":"2019","journal-title":"Clin Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S1470-2045(15)70167-1","article-title":"A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies","volume":"16","author":"Rini","year":"2015","journal-title":"Lancet Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1158\/1078-0432.CCR-18-0323","article-title":"Validation of the 16-gene recurrence score in patients with locoregional, high-risk renal cell carcinoma from a phase III trial of adjuvant sunitinib","volume":"24","author":"Rini","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet Lond Engl."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2019.05.022","article-title":"Updated European Association of urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic clear-cell renal cell carcinoma","volume":"76","author":"Albiges","year":"2019","journal-title":"Eur Urol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1158\/1078-0432.CCR-14-1128","article-title":"Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting","volume":"21","author":"Beuselinck","year":"2015","journal-title":"Clin Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med."}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fsurg.2020.00026\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T04:26:16Z","timestamp":1591331176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fsurg.2020.00026\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":31,"alternative-id":["10.3389\/fsurg.2020.00026"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2020.00026","relation":{},"ISSN":["2296-875X"],"issn-type":[{"type":"electronic","value":"2296-875X"}],"subject":[],"published":{"date-parts":[[2020,6,5]]},"article-number":"26"}}